Enhancement of antidepressant potency by a potentiator of AMPA receptors

Cellular and Molecular Neurobiology

Volumn 23, Issue 3, 2003, Pages 419-430

  Li, Xia ^a   Witkin, Jeffrey M ^a   Need, Anne B ^a   Skolnick, Phil ^b  

^a ELI LILLY AND COMPANY   (United States)

^b DOV Pharmaceutical Inc   (United States)

Author keywords

AMPA receptors; Antidepressants; Behavioral despair; Biogenic amines; Citalopram; Duloxetine; Fluoxetine; Forced swim test; Imipramine; LY 392098; Nisoxetine; Rolipram; Tranylcypromine

Indexed keywords

1 AMINOCYCLOPROPANECARBOXYLIC ACID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; CITALOPRAM; CX 731; DIZOCILPINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LY 392098; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N2 [4 (3 THIENYL)PHENYL]PROPYL 2 PROPANESULFONAMIDE; NISOXETINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZINC ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOGENIC MONOAMINES; BRAIN; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID AGONISTS; MALE; MICE; NEURONS; RECEPTORS, AMPA; SEROTONIN UPTAKE INHIBITORS; SULFONAMIDES; THIOPHENES;

ANIMALIA;

EID: 0038728431     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023648923447     Document Type: Article

References (41)

1. Bai, F., Li, X., Clay, M., Lindstrom, T., and Skolnick, P. (2001). Intra- and interstrain differences in models of "behavioral despair." Pharmacol. Biochem. Behav. 70:187-192.
2. Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., and Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry. 47:351-354.
3. Borsini, F., and Meli, A. (1988). Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology. 94:147-160.
4. Caldecott-Hazard, S., Morgan, D. G., DeLeon-Jones, F., Overstreet, D. H., and Janowsky, D. (1991). Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. Synapse 9:251-301.
5. Cryan, J. F., Markou, A., and Lucki, I. (2002). Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol. Sci. 23:238-45.
6. Daly, J. (1977). Cyclic Nucleotides in the Nervous System, Plenum Press, New York.
7. Duman, R. S., Heninger, G. R., and Nestler, E. J. (1997). A molecular and cellular theory of depression. Arch. Gen. Psychiatr. 54:597-606.
8. Eckmann, F., Fichte, K., Meya, U., and Sastre-Y-Hernandez, M. (1988). Rolipram in major depression: Results of a double-blind comparative study with amitriptyline. Curr. Ther. Res. 43:291-295.
9. Finney, D. J. (1964). Statistical Methods in Biological Assay, 2nd edn., Hafner, New York.
10. Fleischhacker, W. W., Hinterhuber, H., Bauer, H., Pflug, B., Berner, P., Simhandl, C., Wolf, R., Gerlach, W., Jaklitsch, H., and Sastre-y-Hernandez, M. (1992). A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorders. Neuropsychobiology 26:59-64.
11. Hall, J., Thomas, K. L., and Everitt, B. J. (2000). Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. Nat. Neurosci. 3:533-535.
12. Kent, J. M. (2000). SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet 355:911-918
13. Knapp, R. J., Goldenberg, R., Shuck, C., Cecil, A., Watkins, J., Miller, C., Crites, G., and Malatynska, E. (2002). Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur. J. Pharmacol. 440:27-35.
14. Kroczka, B., Branski, P., Palucha, A., Pilc, A., and Nowak, G. (2001). Antidepressant-like properties of zinc in rodent forced swim test. Brain Res. Bull. 15:297-300.
15. Kroczka, B., Zieba, A., Dudek, D., Pilc, A., and Nowak, G. (2000). Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol. J. Pharmacol. 52:403-406.
16. Lauterborn, J. C., Rivera, S., Stinis, C. T., Hayes, V. Y., Isackson, P. J., and Gall, C. M. (1996). Differential effects of protein synthesis inhibition on the activity-dependent expression of BDNF transcripts: evidence for immediate-early gene responses from specific promoters. J. Neurosci. 16:7428-7436.
17. Li, X., Tizzano, J. P., Griffey, K., Clay, M., Lindstrom, T., and Skolnick, P. (2001). Antidepressant-like action of an AMPA receptor potentiator (LY 392098) Neuropharmacology 40:1028-1033.
18. Mackowiak, M., O'Neill, M., Hicks, C., Bleakman, D., and Skolnick, P. (2002). An AMPA receptor potentiator modulates hippocampal expression of BDNF: An in vivo study. Neuropharmacology 43:1-10.
19. Maj, J., Rogoz, Z., Skuza, G., and Sowinska, H. (1992). Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropsychopharmacol. 2:37-41.
20. Nibuya, M., Morinobu, S., and Duman, R. S. (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15:7539-7547.
21. Page, M. E., Detke, M. J., Dalvi, A., Kirby, L. G., and Lucki, I. (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl). 147:162-167.
22. Papp, M., and Moryl, E. (1994). Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263:1-7.
23. Papp, M., and Moryl, E. (1996). Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur. J. Pharmacol. 316:145-151.
24. Paul, I. A. (2001). Excitatory amino acid signaling, major depression and the actions of antidepressants. Pharmaceut. News 8:33-44.
25. Paul, I. A., Nowak, G., Layer, R. T., Popik, P., and Skolnick, P. (1994). Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269:95-102.
26. Petrie, R. X., Reid, I. C., and Stewart, C. A. (2000). The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. Crit. Rev. Pharmacol. Ther. 87:11-25.
27. Porsolt, R. D., Bertin, A., and Jalfre, M. (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229:327-336.
28. Porsolt, R. D., and Lenegre, A. (1992). Behavioural models of depression. In Elliott, J., Heal, D. J., and Marsden, C. A., (eds.), Experimental Approaches to Anxiety and Depression, Wiley, London, pp. 73-85.
29. Rogoz, Z., Skuza, G., Maj, J., and Danysz, W. (2002). Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 42:1024-1030.
30. Rossby, S. P., and Sulser, F. (1997). Antidepressants: Beyond the synapse. In Skolnick, P. (ed.), Antidepressants: New Pharmacological Strategies, Humana Press, Totowa, pp. 195-212.
31. Schneider, H. H. (1984). Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochemi. Pharmacol. 33:1690-1693.
32. Shirayama, Y., Chen, A. C., Nakagawa, S., Russell, D. S., and Duman, R. S. (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22:3251-3261.
33. Siuciak, J. A., Lewis, D. R., Wiegand, S. J., and Lindsay, R. M. (1997). Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56:131-137.
34. Skolnick, P. (1999). Antidepressants for the new millennium. Eur. J. Pharmacol. 375:31-41.
35. Skolnick, P., Legutko, B., Li, X., and Bymaster, F. P. (2001). Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol. Res. 43:411-43.
36. Snedecor, G. W., and Cochran, W. G. (1967). Statistical Methods, Iowa State University Press, Iowa, pp. 135-171.
37. Svenningsson, P., Tzavara, E. T., Witkin, J., Fienberg, A. A., Nomikos, G. G., and Greengard, P. (2002). Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. 99:3182-3187.
38. Trullas, R. (1997). Functional NMDA antagonists: A new class of antidepressant agents. In Skolnick, P. (ed.), Antidepressants: New Pharmacological Strategies, Humana Press, Totowa, pp. 103-124.
39. Willner, P. (1997). Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology (Berl). 134:319-329.
40. Willner, P., and Papp, M. (1997). Animal models to detect antidepressants: Are new models necessary to detect new agents? In Skolnick, P. (ed.). Antidepressants: New Pharmacological Strategies, Humana Press, Totowa, pp. 213-34.
41. Yilmaz, A., Schulz, D., Aksoy, A., and Canbeyli, R. (2002) Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 71:341-344.